PATENT CLAIM ANALYSIS

Application Number: 16400198
Application Type: Utility
Filing Date: 2019-05
Publication Date: 2019-08
Patent Classification: ["530", "388220"]

Abstract:
The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the Lymphocyte Activation Gene-3 (LAG-3). The invention provides a LAG-3-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the LAG-3-binding agent to treat a disorder or disease that is responsive to LAG-3 inhibition, such as cancer or an infectious disease.

Claim (Index 70):
The method of  claim 63 , wherein the cancer is selected from melanoma, renal cell carcinoma, lung cancer, bladder cancer, breast cancer, cervical cancer, colon cancer, gall bladder cancer, laryngeal cancer, liver cancer, thyroid cancer, stomach cancer, salivary gland cancer, prostate cancer, pancreatic cancer, or Merkel cell carcinoma.

Metadata:
- Claim Count in Document: 59.0
- Percentile: 100.0
- Lexical Diversity: 1.78
- Patent Class: 530.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15563924', '15567045', '12599430', '11323261', '11929729']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7622786340992455
- 35 USC 102 Novelty (BERT): 0.6212635865244832
- Combined Prediction Score: 0.7481771293417693
- Mean Citation Score: 478.760874
- Max Citation Score: 593.3006
- Similarity Product: 524.4233433611752

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test